Viral vector unlikely to be cause of leukemia in gene therapy patient
By Jocelyn Kaiser,
Science
| 03. 10. 2021
Photo by Paweł Czerwiński on Unsplash
Gene therapy researchers are breathing easier after a company reported today that the modified virus it used to treat sickle cell disease in a person who later developed leukemia was very unlikely to have caused the cancer.
The leukemia case, which Bluebird Bio disclosed on 16 February, led the company to halt its two sickle cell disease trials and suspend sales of a similar treatment for beta-thalassemia. The following week, the U.S. Food and Drug Administration (FDA) put a hold on the company’s two sickle cell disease trials and two beta-thalassemia trials.
But the company has now done various lab tests and found “important evidence demonstrating that it is very unlikely our BB305 lentiviral vector played a role in this case,” said Chief Scientific Officer Philip Gregory in a press release. The company is now in discussions with FDA about lifting the trial hold.
The studies use a modified virus called a lentivirus to insert a curative gene into the chromosomes of patients’ blood stem cells. About 2 decades ago, a different...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Jessica Mouzo, El País | 10.03.2025
DNA is the molecule of life: this double-helix structure, present in every cell in the body and organized into fragments called genes, stores the instructions for making organisms function. It is a highly precise biological machine, but sometimes it breaks...
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...